RET (S891A)

RET · Variant type: point · HGVS: p.S891A

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Selpercatinib	99.9%	0.1%	96.72
2	Tivozanib	99.8%	0.2%	92.42
3	Pralsetinib	99.7%	0.3%	93.43
4	Alpelisib	99.5%	0.5%	97.22
5	Fedratinib	99.5%	0.5%	96.21
6	Brigatinib	99.4%	0.6%	82.96
7	Erdafitinib	99.2%	0.8%	95.71
8	Lenvatinib	99.2%	0.8%	97.74
9	Ponatinib	99.2%	0.8%	78.23
10	Entrectinib	99.2%	0.8%	93.69
11	Regorafenib	98.9%	1.1%	95.99
12	Sorafenib	98.8%	1.2%	96.72
13	Alectinib	98.8%	1.2%	95.49
14	Nintedanib	98.7%	1.3%	90.23
15	Tenalisib	98.4%	1.6%	97.98
16	Gilteritinib	98.3%	1.7%	88.97
17	Cabozantinib	98.0%	2.0%	92.73
18	Pazopanib	97.6%	2.4%	97.49
19	Axitinib	97.4%	2.6%	93.23
20	Vandetanib	97.1%	2.9%	95.74
21	Futibatinib	96.9%	3.1%	98.48
22	Repotrectinib	96.6%	3.4%	84.21
23	Apatinib	95.7%	4.3%	97.73
24	Sunitinib	94.5%	5.5%	91.73
25	Quizartinib	93.6%	6.4%	99.50

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Selpercatinib	99.9%	100.0%	-0.1%
Tivozanib	99.8%	99.7%	+0.0%
Pralsetinib	99.7%	100.0%	-0.3%
Alpelisib	99.5%	99.6%	-0.1%
Fedratinib	99.5%	99.9%	-0.4%
Brigatinib	99.4%	94.9%	+4.6%
Erdafitinib	99.2%	94.7%	+4.6%
Lenvatinib	99.2%	98.8%	+0.4%
Ponatinib	99.2%	100.0%	-0.8%
Entrectinib	99.2%	99.6%	-0.4%
Regorafenib	98.9%	98.7%	+0.2%
Sorafenib	98.8%	94.0%	+4.9%
Alectinib	98.8%	97.8%	+1.0%
Nintedanib	98.7%	100.0%	-1.3%
Tenalisib	98.4%	98.5%	-0.1%
Gilteritinib	98.3%	100.0%	-1.7%
Cabozantinib	98.0%	97.5%	+0.5%
Pazopanib	97.6%	—	—
Axitinib	97.4%	—	—
Vandetanib	97.1%	98.6%	-1.4%
Futibatinib	96.9%	97.7%	-0.8%
Repotrectinib	96.6%	—	—
Apatinib	95.7%	—	—
Sunitinib	94.5%	97.2%	-2.7%
Quizartinib	93.6%	—	—

Cancer	Organ	Source
carcinoma_thyroid	Thyroid	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.6ms